SAN DIEGO, July 29, 2014 /PRNewswire/ -- Sequenom, Inc.
(NASDAQ: SQNM), a life sciences company that provides innovative
genetic analysis solutions, and Mayo Medical Laboratories (MML),
the third-largest provider of esoteric laboratory services in
the United States, have announced
a license agreement for noninvasive prenatal testing patents and
applications.
"We have great appreciation for Mayo Clinic's commitment to
research, innovation, and patient care, and we welcome the
opportunity to partner with the organization's leading clinical
research laboratory to expand patient access to this revolutionary
technology," said William Welch,
chief executive officer of Sequenom, Inc.
Sequenom Laboratories first pioneered the use of noninvasive
prenatal testing in 2011 with the introduction of the
MaterniT21™ PLUS laboratory-developed test that has
helped more than 250,000 pregnant women worldwide who are at a high
risk for fetal chromosomal abnormalities. A December 2012 joint committee opinion from the
American Congress of Obstetricians and Gynecologists and the
Society of Maternal Fetal Medicine supports the use of cell-free
fetal DNA testing as an option for primary screening for pregnant
women at increased risk of aneuploidy (abnormal chromosomal
number), including those 35 years of age or older or who have a
history of ultrasound abnormalities in pregnancy.
Terms of the agreement were not disclosed.
About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a
life sciences company committed to improving health care through
revolutionary genomic and genetic analysis solutions. Sequenom
develops innovative technologies, products, and diagnostic tests
that target and serve molecular diagnostic markets. Web site:
www.sequenom.com
About Sequenom Laboratories
Sequenom Laboratories, a
CAP-accredited and CLIA-certified molecular diagnostics laboratory,
has developed a broad range of laboratory tests, with a focus on
prenatal and ophthalmological diseases and conditions. Branded
under the names HerediT™, MaterniT21™ PLUS,
RetnaGene™, SensiGene™ and
VisibiliT™, these molecular genetic laboratory-developed
tests provide early patient-management information for
obstetricians, geneticists, maternal fetal medicine specialists,
and ophthalmologists. Sequenom Laboratories is changing the
landscape in genetic-disorder diagnostics using proprietary
cutting-edge technologies.
About Mayo Medical Laboratories and the Mayo
Clinic Department of Laboratory Medicine and Pathology
Mayo
Medical Laboratories is the largest for-profit company associated
with Mayo Clinic, the world-renowned health care organization
located in Rochester, Minnesota.
MML is the third-largest provider of esoteric laboratory services
in the United States and serves
more than 5,000 clients in 130 countries. Mayo Clinic's Department
of Laboratory Medicine and Pathology maintains an active diagnostic
test-development program. These activities also incorporate
technologies from collaborations with diagnostic and biotechnology
companies. Mayo Clinic utilizes these proven diagnostic
technologies in the care of its patients and offers them to health
care institutions through Mayo Medical Laboratories. Revenue from
this testing is used to support medical education and research at
Mayo Clinic.
Mayo Clinic is a nonprofit worldwide leader in medical care,
research, and education for people from all walks of life. For more
information, visit mayoclinic.com or mayoclinic.org/news.
Journalists can become a member of the Mayo Clinic News Network for
the latest health, science, and research news and access to video,
audio, text, and graphic elements that can be downloaded or
embedded.
SEQUENOM®, HerediT™,
MaterniT21™ PLUS, RetnaGene™,
SensiGene™, and VisibiliT™ are trademarks of
Sequenom, Inc. All other trademarks and service marks are the
property of their respective owners.
Forward-Looking Statement
Except for the historical
information contained herein, the matters set forth in this press
release, including statements regarding Sequenom's expectations
related to future performance under the agreement between Sequenom
and Mayo Medical Laboratories, the expected or potential benefits
and impact of the agreement on Sequenom, patients and physicians,
Sequenom's commitment to improving health care through
revolutionary genomic and genetic analysis solutions, and Sequenom
Laboratories' changing the landscape in genetic disorder
diagnostics, are forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are subject to
risks and uncertainties that may cause actual results to differ
materially, including the risks and uncertainties associated with
market demand for and acceptance and use of technology and tests
such as the MaterniT21 PLUS test, reliance upon the collaborative
efforts of other parties and licensees such as Mayo Medical
Laboratories, healthcare providers and others, Sequenom or third
parties obtaining or maintaining regulatory approvals that impact
Sequenom's business, government regulation particularly with
respect to diagnostic products and laboratory developed tests,
publication processes, the performance of designed product
enhancements, Sequenom's ability to develop and commercialize
technologies and products, particularly new technologies such as
noninvasive prenatal diagnostics and laboratory developed tests,
Sequenom's financial position, the timing and amount of
reimbursement that Sequenom Laboratories receives from payors for
its laboratory developed tests, Sequenom's ability to manage its
existing cash resources or raise additional cash resources,
competition, intellectual property protection and intellectual
property rights of others, litigation involving Sequenom, and other
risks detailed from time to time in Sequenom's most recently filed
reports on Form 8-K, its most recently filed Quarterly Report on
Form 10-Q and its Annual Report on Form 10-K for the year ended
December 31, 2013, and other
documents subsequently filed with or furnished to the Securities
and Exchange Commission. These forward-looking statements are based
on current information that may change and you are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. All
forward-looking statements are qualified in their entirety by this
cautionary statement, and Sequenom undertakes no obligation to
revise or update any forward-looking statement to reflect events or
circumstances after the issuance of this press release.
![SEQUENOM logo. SEQUENOM logo.](http://photos.prnewswire.com/prnvar/20040415/SQNMLOGO)
Logo -
http://photos.prnewswire.com/prnh/20040415/SQNMLOGO
SOURCE Sequenom, Inc.